# The Influence of Timing of Cabergoline Initiation on Prevention of OHSS

> **NCT02620605** · PHASE3 · UNKNOWN · sponsor: **Mona M Shaban** · enrollment: 75 (estimated)

## Conditions studied

- Ovarian Hyperstimulation Syndrome

## Interventions

- **DRUG:** Late Cabergoline 0.5mg
- **DRUG:** Early Cabergoline 0.5mg

## Key facts

- **NCT ID:** NCT02620605
- **Lead sponsor:** Mona M Shaban
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-20
- **Primary completion:** 2018-12
- **Final completion:** 2019-04
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2018-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620605, "The Influence of Timing of Cabergoline Initiation on Prevention of OHSS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02620605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*